Oncolab Diagnostics

Our core services are geared towards clinical haematologists, medical oncologists, radiation oncologists and the broader pharmaceutical industry. We currently support some of South Africas largest oncology and haematology practices. Oncolab was established in 2019 through the partnership between SAs leading oncology company, Eurolab, and Alberts Cellular Therapy (ACT), to provide a comprehensive service previously not available in South Africa. Our vision is aligned to bring down cancer treatment costs and expand access to the latest treatment while supporting healthcare professionals and their patients from diagnosis through treatment

Next generation sequencing,cytochemistry,cytogenetic karyotyping,flow cytometry,haematology,bone marrow aspirate and biopsy,cell culture,fluorescent in situ hybridisation (fish),polymerase chain reaction (pcr),hla typing,tp53 mutation,myeloid assay,lymphoma assay,ighv mutational testing (cll),cell-free colon assay,genotyping through rt-pcr,chimerism monitoring through rt-pcr,bcr/abl rq-pcr,full range for haematological malignancies,leukaemia and lymphoma immunophenotyping,minimal residual disease estimation (aml,b-all,t-all,myeloma,lymphoma,cll),myeloma panel on sorted plasma cells,and abo typing (forward and reverse)

Oncolab diagnostics operates in the Hospitals and health care industry.

Oncolab diagnostics's revenue is 11m - 100m

Oncolab diagnostics has 11 - 50 employees.